To effectively respond to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an increasing number of researchers are focusing on the antiviral activity of cepharanthine (CEP), which is a clinically approved drug being used for over 70 years. This review aims to provide a brief overview of CEP and summarize its recent findings in quantitative analysis, pharmacokinetics, therapeutic potential, and mechanism in antiviral and anti-SARS-CoV-2 activity. Given its remarkable capacity against SARS-CoV-2 infection and , with its primary target organ being the lungs, and its good pharmacokinetic profile; mature and stable manufacturing technique; and its advantages of safety, effectiveness, and accessibility, CEP has become a promising drug candidate for treating COVID-19 despite being an old drug.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423819 | PMC |
| http://dx.doi.org/10.3389/fphar.2023.1098972 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Combating COVID-19 and its co-infection by Aspergillus tamarii SP73-EGY using in vitro and in silico Studies.
Sci Rep
January 2025
Chemistry of Natural and Microbial Products Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre, 33 El Buhouth St, Dokki-Giza, Egypt.
The COVID-19 pandemic has caused significant mortality and morbidity for millions of people. Severe Acute Respiratory Syndrome-2 (SARS-CoV-2) virus is capable of causing severe and fatal diseases. We evaluated the antiviral properties of Aspergillus tamarii SP73-EGY isolate extract against low pathogenic coronavirus (229E), Adeno-7- and Herpes-2 viruses.
View Article and Find Full Text PDFImpact of COVID-19, lockdowns and vaccination on immune responses in a HIV cohort in the Netherlands.
Front Immunol
January 2025
Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands.
Article Synopsis
- The COVID-19 pandemic influenced population-level immune responses through infections, lockdowns, and vaccination efforts, potentially impacting various immune-mediated diseases.
- In a study of 1,895 asymptomatic individuals living with HIV, researchers assessed how these factors modified inflammatory profiles and immune responses between October 2019 and October 2021.
- Results showed that while mild COVID-19 infections had minimal long-term immune effects, lockdowns significantly increased immune responsiveness, and vaccinations moderately reduced it, suggesting lockdowns may have unexpected immunological consequences that warrant further investigation.
High-throughput screening of dual-target inhibitors for SARS-CoV-2 main protease and papain-like protease from Chebulae Fructus: prediction and experimental verification.
Front Microbiol
December 2024
State Key Laboratory of Chinese Medicine Modernization, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Background: The unavoidable propagation of the coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has underscored the urgent requirement for efficacious therapeutic agents. The dried fruit of Retz., namely Chebulae Fructus, is widely used for treating bacterial and viral infectious diseases, which was witnessed to perform anti-SARS-CoV-2 activity in recommended Chinese patent medicine.
View Article and Find Full Text PDFDesign, synthesis, and biological evaluation of novel 2'-deoxy-2'-spirooxetane-7-deazapurine nucleoside analogs as anti-SARS-CoV-2 agents.
Antiviral Res
December 2024
State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Science, Guangzhou, 510530, China; Guangzhou Henovcom Bioscience Inc, 11 Kaiyuan Rd, Guangzhou, Guangdong, China. Electronic address:
Article Synopsis
- The COVID-19 pandemic, driven by the SARS-CoV-2 virus, poses ongoing health risks and highlights the need for new antiviral treatments due to the virus's ability to mutate.
- Researchers designed and synthesized new 2'-deoxy-2'-spirooxetane-7-deazapurine nucleoside analogs to inhibit the replication of SARS-CoV-2.
- Among these, nucleoside analog 11q showed the strongest antiviral effects, outperforming existing treatments like Remdesivir and indicating its potential as a future therapeutic option.
Colloidal ZnAl-Layered Double Hydroxide Nanomaterials for Effective Prevention of SARS-CoV-2.
ACS Appl Bio Mater
December 2024
Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China.
SARS-CoV-2 is a threat to global public health, which requires the development of safe measures to reduce the spread of this coronavirus. Herein, in this study, we prepared and examined potential antiviral agents based on ZnAl-layered double hydroxide (ZnAl-LDH) materials. ZnAl-LDH-based samples were synthesized via a one-pot low-temperature coprecipitation method, which features an ultrathin structure.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!